Seminars in Immunology, Год журнала: 2024, Номер 76, С. 101911 - 101911
Опубликована: Ноя. 1, 2024
Язык: Английский
Molecular Cancer, Год журнала: 2025, Номер 24(1)
Опубликована: Янв. 13, 2025
This review highlights recent progress in exosome-based drug delivery for cancer therapy, covering exosome biogenesis, cargo selection mechanisms, and their application across multiple types. As small extracellular vesicles, exosomes exhibit high biocompatibility low immunogenicity, making them ideal vehicles capable of efficiently targeting cells, minimizing off-target damage side effects. aims to explore the potential with a focus on applications chemotherapy, gene immunomodulation. Additionally, challenges related production standardization are analyzed, highlighting importance addressing these issues clinical application. In conclusion, systems offer promising future therapies. Further research should aim enhance efficiency facilitate translation, paving way innovative treatment strategies.
Язык: Английский
Процитировано
10
Onco, Год журнала: 2025, Номер 5(1), С. 2 - 2
Опубликована: Янв. 2, 2025
The integration of small interfering RNA (siRNA) with traditional cancer therapies represents a promising frontier in oncology aimed at enhancing treatment effectiveness, reducing side effects, and overcoming drug resistance. This review highlights the potential siRNA to selectively silence genes that are overexpressed or uniquely expressed cells, thereby disrupting critical pathways support tumor growth survival. Key target discussed include survivin, VEGF, EGFR, c-MET, HER2, MUC1, Bcl-2, all which play vital roles proliferation, angiogenesis, resistance therapies. Clinical trials investigating various candidates, such as EZN-3042 ALN-VSP, indicate these generally well-tolerated; however, significant challenges persist, including effective delivery stability siRNA. Recent advancements nanoparticle-based systems have shown promise addressing issues. Future research will focus on optimizing methods, personalizing based individual genetic profiles, establishing clearer regulatory guidelines for approval. As field evolves, siRNA-based combination poised become an integral part precision oncology, offering new therapeutic options hope patients difficult-to-treat cancers.
Язык: Английский
Процитировано
0
IBRO Neuroscience Reports, Год журнала: 2025, Номер 18, С. 323 - 337
Опубликована: Фев. 6, 2025
Non-coding accounts for 98 %-99 % of the human genome and performs many essential regulatory functions in eukaryotes, involved cancer development development. RNAs are abundantly enriched exosomes, which play a biological role as vectors. Some biofunctional non-coding specifically designed exosomes treatment cancers such glioma. Glioma is one most common primary tumors within skull has varying degrees malignancy histologic subtypes grades I-IV. Gliomas characterized by high an abundant blood supply due to rapid cell proliferation vascularization, often with poor prognosis. Exosomal can be tumorigenesis process glioma from multiple directions, angiogenesis, tumor proliferation, metastatic invasion, immune evasion, apoptosis, autophagy. Therefore, suitable markers or therapeutic targets early diagnosis diseases predicting prognosis variety diseases. Regulating exosome production level exosomal RNA expression may new approach prevent eliminate In this review, we review origin characteristics RNAs, introduce functional studies their potential clinical applications, order broaden ideas
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(6), С. 940 - 940
Опубликована: Март 10, 2025
Exosomes have emerged as pivotal players in precision oncology, offering innovative solutions to longstanding challenges such metastasis, therapeutic resistance, and immune evasion. These nanoscale extracellular vesicles facilitate intercellular communication by transferring bioactive molecules that mirror the biological state of their parent cells, positioning them transformative tools for cancer diagnostics therapeutics. Recent advancements exosome engineering, artificial intelligence (AI)-driven analytics, isolation technologies are breaking barriers scalability, reproducibility, clinical application. Bioengineered exosomes being leveraged CRISPR-Cas9 delivery, while AI models enhancing biomarker discovery liquid biopsy accuracy. Despite these advancements, key obstacles heterogeneity populations lack standardized protocols persist. This review synthesizes pioneering research on biology, molecular translation, emphasizing dual roles both mediators tumor progression intervention. It also explores emerging areas, including microbiome–exosome interactions integration machine learning exosome-based medicine. By bridging innovation with translational strategies, this work charts a forward-looking path integrating into next-generation care, setting it apart comprehensive guide overcoming technological hurdles rapidly evolving field.
Язык: Английский
Процитировано
0
BIO Integration, Год журнала: 2025, Номер 6(1)
Опубликована: Янв. 1, 2025
Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition and tissue scarring, leading to impaired function respiratory failure. Although current treatments, such as pirfenidone nintedanib, slow progression, they fail completely halt or reverse fibrosis. Therefore, innovative therapeutic strategies are needed. Targeted drug delivery systems (TDDSs) emerging promising solutions. Biomaterials play critical roles in these enhancing specificity, availability, efficacy, while minimizing systemic toxicity. The most notable biomaterials include nanotechnology-based systems, including liposomes polymeric nanoparticles, which facilitate penetration release fibrotic tissues. Hydrogels have three-dimensional structures providing controlled sustained at inflammation sites, therefore particularly valuable PF treatment. Furthermore, biological carriers stem cells vesicles biocompatibility anti-inflammatory effects that improve outcomes. Despite the potential of clinical translation hindered several challenges, immune clearance, stability platforms, optimization retention within diseased Interdisciplinary approaches integrating precision medicine with advancements may provide solutions opening new avenues for This review discusses developments targeted PF, emphasizing importance biomaterials, mechanisms barriers involved pulmonary delivery, future perspectives overcoming limitations. ultimate goal patient outcomes revolutionizing approach treatment through advanced technologies.
Язык: Английский
Процитировано
0
Pathology - Research and Practice, Год журнала: 2024, Номер 266, С. 155785 - 155785
Опубликована: Дек. 19, 2024
Язык: Английский
Процитировано
1
Seminars in Immunology, Год журнала: 2024, Номер 76, С. 101911 - 101911
Опубликована: Ноя. 1, 2024
Язык: Английский
Процитировано
0